Featured Research

from universities, journals, and other organizations

Researchers identify priority targets for immunotherapy in epithelial ovarian cancer

Date:
August 13, 2014
Source:
Roswell Park Cancer Institute
Summary:
Expression of MAGE cancer-testis antigens correlates with clinical outcome in epithelial ovarian cancer, researchers report, and that several of these unique proteins may prove to be prognostic factors for ovarian cancer.

Researchers at Roswell Park Cancer Institute (RPCI) have found that the expression pattern of a unique class of tumor-associated antigens, known as the MAGE cancer-testis antigens (CTAs), correlates with clinical outcome in epithelial ovarian cancer. Based on their findings, the researchers have identified priority targets for ovarian cancer immunotherapy.

Related Articles


Epithelial ovarian cancer is the most lethal gynecologic cancer in women and has a relapse rate of 85%.

"The MAGE family of proteins is part of a class of CTAs that may serve as a target for directed immunotherapy in ovarian cancer and other types of cancer," said senior author Kunle Odunsi, MD, PhD, FRCOG, FACOG, M. Steven Piver Professor of Gynecologic Oncology and Executive Director of the Center for Immunotherapy at RPCI. "To achieve the important goal of tumor-directed immunity for ovarian cancer immunotherapy, it is critical to determine the extent to which this family of CTA molecules is expressed in these tumor cells."

Dr. Odunsi and his colleagues examined the expression pattern of five MAGE molecules using genetic and immunohistochemical screens in tissue samples of 400 patients with ovarian cancer. They analyzed immune responses by determining whether antibodies present in 285 serum samples recognized the same five molecules. Their results revealed that aberrant expression of MAGE-A1 was present in 15% of epithelial ovarian cancers, expression of MAGE-A3 was present in 36%, expression of MAGE-A4 was present in 47%, expression of MAGE-A10 was present in 52%, and expression of MAGE-C1/CT7 was present in 16%.

"Approximately 78% of ovarian tumor tissue showed expression of at least one of these five CTAs," Dr. Odunsi said.

Researchers also noted strong co-expression of MAGE-A1 and MAGE-A4, MAGE-A1 and MAGE-C1, and MAGE-A4 and MAGE-A10. MAGE-A1 and MAGE-A10 expression were associated with poor progression-free survival, while MAGE-C1/CT7 was associated with improved progression-free survival, although this improvement diminished with the co-expression of MAGE-A1 or MAGE-A10.

According to Dr. Odunsi, these results suggest that MAGE-A1, MAGE-A10 and MAGE-C1 are possible prognostic factors for ovarian cancer. In addition, "as MAGE-A4 exhibits a relatively high frequency of expression and appears to direct a major pattern of co-expression of other MAGE antigens, we also propose MAGE-A4 as a priority target for ovarian cancer immunotherapy," he said.

RPCI researchers are also conducting clinical trials, including vaccination studies and adoptive cell therapy, using another CTA known as NY-ESO-1. "Because not all ovarian tumors express NY-ESO-1, it is critical to identify other potential targets for immunotherapy," Dr. Odunsi noted. "The current study supports the development of MAGE-directed immunotherapies to provide alternative modalities for patients whose tumors do not express NY-ESO-1 or whose responses against NY-ESO-1-expressing tumors are no longer sufficient."


Story Source:

The above story is based on materials provided by Roswell Park Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sayeema Daudi, Kevin H. Eng, Paulette Mhawech-Fauceglia, Carl Morrison, Anthony Miliotto, Amy Beck, Junko Matsuzaki, Takemasa Tsuji, Adrienne Groman, Sacha Gnjatic, Guillo Spagnoli, Shashikant Lele, Kunle Odunsi. Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer. PLoS ONE, 2014; 9 (8): e104099 DOI: 10.1371/journal.pone.0104099

Cite This Page:

Roswell Park Cancer Institute. "Researchers identify priority targets for immunotherapy in epithelial ovarian cancer." ScienceDaily. ScienceDaily, 13 August 2014. <www.sciencedaily.com/releases/2014/08/140813173652.htm>.
Roswell Park Cancer Institute. (2014, August 13). Researchers identify priority targets for immunotherapy in epithelial ovarian cancer. ScienceDaily. Retrieved March 30, 2015 from www.sciencedaily.com/releases/2014/08/140813173652.htm
Roswell Park Cancer Institute. "Researchers identify priority targets for immunotherapy in epithelial ovarian cancer." ScienceDaily. www.sciencedaily.com/releases/2014/08/140813173652.htm (accessed March 30, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 30, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins